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SUMMARY STATEMENT 
This paper demonstrates a functional link between a cancer–associated alteration to 
the tRNA repertoire and the invasive behaviour of cancer cells.    
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ABSTRACT 
The cell’s repertoire of transfer RNAs (tRNAs) has been linked to cancer. Recently, 
levels of the initiator methionine tRNA (tRNAiMet) in stromal fibroblasts have been 
shown to influence extracellular matrix (ECM) secretion to drive tumour growth and 
angiogenesis.  Here we show that increased tRNAiMet within cancer cells does not 
influence tumour growth, but drives cell migration and invasion via a mechanism that 
is independent from ECM synthesis and dependent on α5β1 integrin and levels of 
the translation initiation ternary complex. In vivo and ex vivo migration (but not 
proliferation) of melanoblasts is significantly enhanced in transgenic mice which 
express additional copies of the tRNAiMet gene.  We show that increased tRNAiMet in 
melanoma drives migratory, invasive behaviour and metastatic potential without 
affecting cell proliferation and primary tumour growth, and that expression of RNA 
polymerase III-associated genes (which drive tRNA expression) are elevated in 
metastases by comparison with primary tumours. Thus specific alterations to the 
cancer cell tRNA repertoire drive a migration/invasion programme that may lead to 
metastasis.   
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INTRODUCTION 
Many of the steps to metastasis require cancer cells to migrate invasively through 
the extracellular matrix (ECM) that surrounds tumours and tissues (Sahai, 2005).  
This type of invasive migration involves coordination of a number of cellular 
processes – such as secretion of degradative factors (for example, matrix 
metalloproteases) to clear a path through the surrounding tissue, engagement of cell 
adhesion receptors (such as α5β1 integrin) with the ECM and recruitment of the 
contractile cytoskeleton to integrins which provides traction force to translocate the 
invading cell away from the primary tumour.  Cancer cells must invoke transcriptional 
programmes to coordinate these various cellular processes. Thus, in addition to 
upregulation of proteins that directly contribute to cell migration, the pro-invasive 
programme involves production of other regulators (such as transcription factors) 
which coordinate expression of pro-migratory and pro-invasive factors (Ozanne et al, 
2000).   
Pro-invasive programmes may also be implemented at the level of the ribosome.  
Indeed, a number of ‘ribosomopathies’ - syndromes with well-characterised 
inheritable mutations in ribosomal subunits or other components of the translation 
machinery – display a marked cancer predisposition (Ganapathi & Shimamura, 
2008; Ruggero, 2013).  Furthermore, key oncogenic pathways such as the PI3K-Akt-
mTOR axis control particular components of the translational machinery, such as the 
eIF4E initiation factor and the S6 ribosomal protein, to modulate selectivity of mRNA 
translation in a way that influences cancer-relevant processes (Ruggero & 
Sonenberg, 2005).  For example, upregulation of mTOR signalling favours 
translation of a number of transcripts for pro-migratory proteins (such as YB1, 
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vimentin and CD44) and it is thought that these can cooperate to promote metastasis 
(Hsieh et al, 2012). A key regulator of the ribosome and the mRNA translation 
machinery is RNA polymerase III (Pol III).  Pol III is the largest of the three eukaryotic 
polymerases and is responsible for transcription of a number of short, non-coding 
RNAs which include transfer RNAs (tRNAs) and RNA ribosomal components. Pol III 
function is controlled by multiple oncogenes and tumour suppressors including c-
myc, p53 and Rb, mooting this RNA polymerase as a potential master regulator of a 
translational programme that contributes to cancer progression (White, 2008).  It has 
been known for some time that expression of certain Pol III target genes, for instance 
tRNAiMet (the initiator methionine tRNA responsible for recognising the start codon 
and initiating translation) is upregulated in cancer and it has been proposed that this 
may drive progression of the disease (Pavon-Eternod et al, 2009; Pavon-Eternod et 
al, 2013).  More recently it has become clear that the cell’s tRNA repertoire differs 
profoundly between different tissues (Dittmar et al, 2006) and between differentiated 
cells and cancer lines (Gingold et al, 2014).  Indeed, proliferating cells have 
increased levels of tRNAs with codons that are particularly abundant in transcripts 
encoding proteins associated with cell growth and proliferation. Thus the tRNAome 
compliments transcriptional programmes to ensure efficient translation of the cohorts 
of transcripts which are associated with particular cellular outcomes .  Consistent 
with previous reports, Gingold et al. report that highly proliferative cancer cell lines 
commonly display increased levels of tRNAiMet (Gingold et al, 2014).  Thus it would 
seem natural to propose that this alteration to the tRNA repertoire would drive 
increased use of the AUG codon leading to upregulation of translation initiation and 
protein synthesis to support cancer cell growth and proliferation.  However, a recent 
study in stromal fibroblasts indicate that elevated levels of tRNAiMet do not directly 
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support increased cellular protein synthesis and proliferation (Clarke et al, 2016).  
Rather, increased tRNAiMet alters the fibroblast secretome to favour synthesis and 
secretion of certain collagens (particularly type II collagen) which are incorporated 
into the tumour extracellular matrix (ECM).  This collagen II-rich ECM supports 
motility of endothelial cells which leads to increased angiogenesis and tumour 
growth.  These findings are consistent with studies in Drosophila indicating that 
increased levels of tRNAiMet drive cellular growth via a non-cell autonomous 
mechanism involving alterations to the cellular secretome (Rideout et al, 2012).  
Indeed, introduction of an extra copy of the tRNAiMet gene into flies is sufficient to 
markedly enhance larval growth which is driven by increased release of insulin-like 
peptides from brain neurosecretory cells which, in turn, circulate throughout the 
embryo to promote growth of developing organs and tissues. 
Because Pol III products are thought to be increased in tumour cells (White, 2005) 
as well as in stromal fibroblasts (Clarke et al, 2016), we have generated approaches 
to manipulate levels of Pol III and its product tRNAiMet in tumour cells and have 
determined the consequences of this on tumour cell behaviour.  Using both in vitro 
and in vivo approaches we show that increased levels of tRNAiMet in tumour cells 
drives metastasis by enlisting integrin-dependent cell migration and invasion without 
influencing cell growth or proliferation indicating that the cell migratory machinery 
responds to alterations in the tRNA repertoire during the metastatic process. 
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RESULTS 
tRNAiMet drives cell migration dependent on α5β1 integrin and the translation 
initiation ternary complex 
An alteration to the tRNA repertoire that is associated with highly aggressive cancer 
cells is elevated levels of the initiator methionine tRNA, tRNAiMet.  As we have 
previously shown that elevated tRNAiMet levels do not lead to upregulated protein 
synthesis, increased cell proliferation (Clarke et al, 2016), or altered energy 
metabolism (not shown) we looked at the ability of this tRNA to influence other cell 
characteristics that are associated with cancer aggressiveness. Initially we compared 
the migratory behaviour of immortalised mouse embryonic fibroblasts (iMEFs) which 
overexpress tRNAiMet (iMEF.tRNAiMet) with those expressing and empty vector as 
control (iMEF.Vector). Two pairs of iMEF pools were used throughout the 
subsequent experiments, with pools 1 and 2 having approximately 15 and 5-fold 
increases in tRNAiMet expression respectively (Clarke et al, 2016), corresponding to 
the range of increased tRNA expression seen in human tumours compared to 
normal tissue (Pavon-Eternod et al, 2009). Overexpression of tRNAiMet significantly 
increased speed of fibroblast migration both into scratch-wounds, and when 
subconfluent cells were moving randomly on plastic surfaces (Fig. 1A).  We used 
siRNA and function blocking antibodies to investigate which adhesion receptors were 
responsible for this altered cell motility. We deployed the mAb16 and 16G3 inhibitory 
monoclonal antibodies which recognise the receptor/ligand binding sites on α5 
integrin and fibronectin respectively, or we used siRNA to suppress levels of α5 
integrin itself (Fig. S1A). Blockade of α5β1-fibronectin interaction with mAb16 or 
16G3, or siRNA knockdown of α5 integrin (using either a SMARTPool or two 
B
io
lo
gy
 O
pe
n 
• 
A
dv
an
ce
 a
rt
ic
le
individual siRNA oligos) suppressed migration of tRNAiMet overexpressing fibroblasts, 
without affecting motility of the appropriate control vector-expressing cells (Fig. 1B). 
We have previously shown that increased levels of tRNAiMet leads to increased 
synthesis and secretion of ECM proteins, in particular type II collagen, and that this 
is responsible for tumour angiogenesis and growth (Clarke et al, 2016).  To 
determine whether tRNAiMet drives cell migration via synthesis of secreted and/or 
ECM factor(s), we collected conditioned medium from iMEF.tRNAiMet and 
iMEF.Vector cells and tested the ability of this to influence fibroblast migration.  
Moreover, we suppressed type II collagen using siRNA or CRISPR (Clarke et al, 
2016) and determined whether this influenced tRNAiMet-driven cell migration.  
However, neither conditioned medium from tRNAiMet-overexpressing cells (Fig. 1C) 
nor siRNA or CRISPR of type II collagen (Fig. 1D) altered the ability of tRNAiMet to 
promote cell migration.  Taken together, these data indicate that tRNAiMet drives cell 
migration via mechanisms that are dependent on engagement of α5β1 integrin, but 
independent from the role that this tRNA plays in controlling the ECM synthesis and 
secretion.   
The role of tRNAiMet in translation initiation is dependent on its ability to associate 
with initiation factor eIF2 and GTP to form the ternary complex (Sonenberg & 
Hinnebusch, 2009), and translation initiation can be controlled by phosphorylation of 
eIF2α. Although we found there to be no consistent difference in phospho-eIF2α 
levels following tRNAiMet overexpression (not shown), indicating that cell migration 
was not dependent on absolute differences in phospho-eIF2α levels, we still 
considered it possible that tRNAiMet levels may influence cell migration by altering 
ternary complex availability. To investigate the dependency of tRNAiMet -driven cell 
migration on TC levels, we used the phosphatase inhibitor, salubrinal, to increase 
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levels of phospho-eIF2α (by inhibiting phospho-eIF2α dephosphorylation) (Fig. 2A) 
(Boyce et al, 2005). Conversely, we overexpressed the protein phosphatase 
regulatory subunit, GADD34, to decrease levels of phospho-eIF2α (by recruiting 
protein phosphatase 1 to dephosphorylate phospho-eIF2α) (Fig. 2B) (Boyce et al, 
2005). Salubrinal treatment increased migration speed of iMEF.Vector cells, but not 
tRNAiMet overexpressing cells (Fig. 2A), whereas expression of GADD34  completely 
reversed the ability of tRNAiMet to promote cell migration (Fig. 2B). Taken together 
these data indicate that tRNAiMet drives cell migration in a way that is dependent on 
levels of the translation initiation ternary complex. 
 
Increased levels of tRNAiMet drive cell migration in vivo 
Having used fibroblast models to establish a role for tRNAiMet in cell motility, we 
wished to determine whether such a relationship could be demonstrated in vivo 
using a transgenic mouse possessing two additional copies of the tRNAiMet gene 
(2+tRNAiMet mouse) and which expresses increased tRNAiMet levels in all tissues 
tested (Clarke et al, 2016).  We looked at the distribution of melanoblasts (neural 
crest-derived precursors of melanocytes) which migrate dorso-ventrally during 
embryogenesis to populate the skin of the mouse (Thomas & Erickson, 2008).  This 
process occurs between days E10 – E15 of embryogenesis, and by E13.5 the 
melanoblasts are en route to the limb extremities and other more ventral regions of 
the embryo. We crossed 2+tRNAiMet mice to a line expressing DCT-LacZ (to 
visualise melanoblasts), and determined the proportion of cells that had moved to 
the distal/ventral regions of the forelimbs at E13.5 (Fig. 3A).  Whilst there was no 
significant difference in the total melanocyte number – indicating no effect of tRNAiMet 
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overexpression on cell proliferation and/or differentiation – a higher proportion of 
melanoblasts had migrated to the limb extremities (regions 4-5 in Fig. 3A) of 
2+tRNAiMet mice than in their littermate controls (Fig. 3B). Given our previous 
observations that the contribution made by increased tRNAiMet levels to tumour 
growth is not cell autonomous, it was necessary to determine whether the influence 
of tRNAiMet overexpression on melanoblast migration was owing to the migratory 
behaviour of the these cells themselves.  To test this, we isolated melanoblasts from 
2+tRNAiMet embryos and measured their migration ex vivo.  [N.B. To enable growth 
of mouse melanoblasts in ex vivo culture we used mice that were null for INK4a and 
that expressed an allele of mutant NRas under a melanoblast-specific promoter 
(Tyr::NrasQ61K/°; INK4a−/−)(Lindsay et al, 2011)].  Melanoblasts isolated from 
2+tRNAiMet mice had elevated levels of tRNAiMet and migrated faster than cells from 
their littermate controls, indicating that the ability of tRNAiMet to promote in vivo 
migration of melanoblasts is likely to be cell-autonomous (Fig. 3C). Taken together, 
these data indicate that, although increased levels of tRNAiMet do not affect cell 
growth proliferation or differentiation, this transfer RNA plays a key role in controlling 
melanoblast migration velocity in vivo and ex vivo.   
 
Increased levels of tRNAiMet drive melanoma invasion and lung colonisation  
A recent study indicates that there are key similarities between the molecular 
machinery involved in the migration of melanoblasts and the drive to metastasis in 
melanoma (Lindsay et al, 2011), prompting us to investigate the role of tRNAiMet in 
the migratory and invasive behaviour of melanoma.  Initially we looked at the WM852 
melanoma cell line and found that the migration speed of these cells was 
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significantly enhanced by overexpression of tRNAiMet (in two independent stable 
pools of cells), but not by the elongator methionine tRNA, tRNAeMet (Fig. 4A; Fig. 
S2A).  Moreover, as for fibroblast migration, the ability of tRNAiMet to influence 
melanoma cell movement was completely dependent on α5β1 integrin (as 
determined using blocking antibodies and siRNA with a SMARTPool and 2 individual 
siRNA oliogonucleotides) and its engagement with fibronectin (Fig. 4B; Fig. S1B).  
To look at the invasive and metastatic characteristics of melanoma cells we used the 
WM266.4 cell line, which was established from a cutaneous melanoma metastasis 
and exhibits moderately invasive behaviour both in vivo and in vitro.  WM266.4 cells 
invade into Matrigel and elevated expression of tRNAiMet increased invasiveness in 
two independent pools of WM266.4 cells, whereas other Pol III products (tRNAeMet & 
a tRNA for threonine, tRNAThr) were ineffective in this regard (Fig. 4C; Fig. S2B). 
Furthermore, overexpression of tRNAiMet did not influence proliferation of WM266.4 
cells, indicating that tRNAiMet’s ability to drive melanoma cell invasion is not mediated 
via increased cell growth (Fig. 4D).   
We then studied the influence of tRNAiMet on tumour growth and lung colonisation 
using subcutaneous and intra-tail vein xenograft approaches respectively.  
Overexpression of tRNAiMet did not influence growth of tumours formed following 
subcutaneous injection of WM266.4 cells, consistent with a lack of a regulatory role 
for this Pol III product in cell growth and proliferation (Fig. 5A). However, Western 
blotting indicated that there was a tendency for the subcutaneous tumours formed 
from tRNAiMet-overexpressing cells to have elevated fibronectin and β1 integrin 
content, suggesting that tRNAiMet may drive α5β1 integrin-dependent processes in 
these tumours (Fig. 5B).  As tumour cell invasiveness can be promoted by α5β1 and 
is often associated with increased fibronectin levels, we injected WM266.4 cells 
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overexpressing tRNAiMet or a control vector (two independent pools of each) into 
CD1 nude mice via the tail vein and measured the capacity of these cells to colonise 
the lung. Upon visual inspection, the lungs of mice injected with tRNAiMet-
overexpressing WM266.4 cells contained more tumours and were heavier than those 
from animals injected with control cells (Fig. 5C, D). To quantify lung tumour burden 
we used qPCR to determine the ratio of human (from the WM266.4 cells) to mouse 
(the host) DNA.  This indicated that the tumour burden in the lungs from the animals 
injected with tRNAiMet overexpressing cells was 2-3 fold higher than their appropriate 
controls (Fig. 5D). Taken together, these data indicate that increased levels of the 
Pol III product, tRNAiMet is sufficient to promote the ability of melanoma to invade into 
and to colonise tissues without influencing the proliferation and growth of the primary 
tumour.   
We wished to determine whether tRNAiMet and other related Pol III products were 
associated with invasion and metastasis in human cancer.  However, because we 
have been unable to obtain comprehensive bioinformatic data concerning the levels 
of tRNAiMet in large cohorts of human tumours, we analysed data from a number of 
publically-available datasets to look at the levels of other transcripts associated with 
Pol III in melanoma and prostate cancer metastases, and compared these with the 
corresponding levels in patient matched primary tumours.  mRNAs encoding for Pol 
III subunits and for a Pol III’s transcription factor, TFIIIC were increased by 1.3-3.5-
fold in metastases from melanoma by comparison with patient-matched primary 
tumours in at least two (Xu and Riker) independent datasets (Fig. 6A & B).  
Moreover, similar upregulation of Pol III-related transcripts in prostate metastases 
was observed in the Grasso dataset (Fig. 6C).  Taken together, these data indicate 
that a number of Pol III products are upregulated as tumours metastasise and that 
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one product in particular – tRNAiMet, is responsible for driving the cell migratory and 
invasive characteristics that leads to tumour dissemination and metastasis.   
 
 
 
DISCUSSION 
In this paper we show that elevated levels of tRNAiMet activate a cell migration 
programme dependent on α5β1 integrin and formation of the translation initiation 
ternary complex.  Furthermore, we show that migration and invasion driven by this 
alteration to the tRNA repertoire may be demonstrated in vivo, and leads to 
upregulation of embryonic melanoblast migration and increased metastasis in a 
xenograft model of melanoma. Importantly, tRNAiMet-dependent invasiveness is 
achieved without any detectable alteration to primary tumour growth or cell 
proliferation, indicating that the tumour cell migratory machinery is likely to be a key 
target of the tRNA repertoire during the metastatic cascade.   
The activity of Pol III has been known for some time to be associated with cancer 
and Pol III transcriptional programmes are regulated by a number of oncogenes and 
tumour suppressors (White, 2008).  However, although all tRNAs are transcribed by 
Pol III there is considerable selectivity in their expression leading to association of 
particular tRNA repertoires with cells that are either actively proliferating or those that 
are  more differentiated and/or quiescent (Gingold et al, 2014).  A combination of 
increased Pol III activity and epigenetic modification of tRNA genes leads to a 
proliferative tRNA repertoire that is characterised by particularly high levels of 
tRNAiMet.  Moreover, tRNAiMet levels are upregulated in stromal cells such as 
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carcinoma-associated fibroblasts (Clarke et al, 2016).  This had initially been 
proposed to reflect a need for global upregulation of translation initiation to support 
increased protein synthesis in rapidly growing cells.  However, our data suggest that 
this is not the case, and that selective upregulation of tRNAiMet contributes to cancer 
via two distinct mechanisms - neither of which directly involve altered cell 
proliferation or growth – but which differ depending on the whether the tRNA is 
elevated in the stromal or cancer cell compartments.  Thus, if tRNAiMet levels are 
elevated in stromal fibroblasts, this leads to highly significant and selective 
alterations to their secretome which drive tumour growth by increasing endothelial 
cell motility to promote tumour angiogenesis (Clarke et al, 2016).  More specifically, 
this is attributable to selective upregulation of synthesis and secretion of type II 
collagen.  By contrast, upregulation of tRNAiMet in tumour cells leads to acquisition of 
migratory and invasive characteristics that are cell autonomous and independent 
from components of the tRNAiMet-driven secretome.   
One possible mechanism for tRNAiMet’s cell autonomous drive to cell migration is via 
generation of microRNA-like molecules.  Recent reports indicate the existence of a 
class of tRNA-derived small RNAs that interact with the RNAi machinery, possibly to 
influence mRNA stability and translation (Pederson, 2010).  However, microRNAs 
are normally thought to suppress cell migration and other characteristics imputed to 
cancer cells – indeed, a microRNA-like molecule derived from the 3’ end of a mature 
tRNA is suppressed in B cell lymphoma (Maute et al, 2013).  Moreover, our data 
indicate that tRNAiMet controls cell migration via a mechanism involving its canonical 
role in translation initiation.  Indeed, we show that levels of the translation initiation 
ternary complex (of which tRNAiMet is a component) are key to control of cell 
migration.  Elevated levels of the ternary complex leads to increased migration 
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speed, and overexpression of GADD34 (to reduce ternary complex levels) 
completely opposes tRNAiMet-driven cell migration without affecting movement of 
cells that do not have elevated levels of tRNAiMet.   
tRNAiMet’s influence on stromal ECM deposition is associated with upregulated 
synthesis of a defined cohort of proteins (Clarke et al, 2016).  We, therefore, 
considered whether tRNAiMet’s ability to drive cell migration may involve altered 
synthesis of particular proteins. Indeed, although the majority of tRNAiMet’s 
translational targets are secretory and/or ECM proteins (and we don’t find tRNAiMet’s 
drive to cell migration to rely on any of these), there are a few cellular proteins whose 
synthesis is promoted by increased levels of tRNAiMet (Clarke et al, 2016). Despite 
these efforts, we have been unable to identify any individual component of the 
cellular tRNAiMet translatome with a clear role in the ability of this tRNA to drive cell 
migration and invasion.  We, therefore, feel that the connection between tRNAiMet 
and the cell migration machinery might be mediated somewhat indirectly. Clearly, 
elevated levels of tRNAiMet are associated with a net shift toward increased 
production of secreted proteins, and this would be expected to be associated with 
increased flux of membrane and protein traffic through elements of the biosynthetic 
secretory pathway – such as the ER, Golgi and post-Golgi compartments.  Such 
generally increased delivery of membrane and protein traffic to the plasma 
membrane would be likely to influence cell migration. Indeed, all of the receptors that 
drive cell migration and invasion are delivered to the cell surface via the trans-Golgi 
network and, more recently, integrins have been shown to recycle via a pathway 
involving elements of the ER and the trans-Golgi network (Reverter et al, 2014; 
Shafaq-Zadah et al, 2016).  Further work will be necessary to determine the 
consequences of upregulated biosynthetic secretory traffic on the trafficking of pro-
B
io
lo
gy
 O
pe
n 
• 
A
dv
an
ce
 a
rt
ic
le
invasive adhesion receptors, and whether this contributes to tRNAiMet’s cell 
autonomous drive to cancer cell invasiveness.   
Many of the components of the tRNAiMet-driven secretome are large proteins which, 
when synthesised in large quantities, would be expected to put considerable 
demands on the biosynthetic and secretory machinery.  Thus it is likely that the 
protein folding and post-translational capacity of the ER is stretched by the 
considerably increased production of collagens which is enlisted following tRNAiMet 
upregulation, and, if so, this would elicit ER stress responses and other cell 
signalling pathways known to relay information from the ER to the nucleus. Indeed, 
ER stress is well-established to influence transcriptional programmes that lead to 
metastasis (Bu & Diehl, 2016), and it will be interesting to determine whether this is 
in part responsible for connecting increased tRNAiMet’s levels to the metastatic 
capacity of cancer cells.  
To conclude, we have identified two distinct, but complementary, mechanisms 
through which a defined alteration to the tRNA repertoire may drive tumour growth 
and metastasis.  Upregulation of tRNAiMet in stromal fibroblasts drives synthesis of a 
collagen II rich ECM which supports angiogenesis and primary tumour growth 
(Clarke et al, 2016), whilst elevated levels of tRNAiMet in the tumour cells influences 
their migratory phenotype to increase their propensity to metastasise.  These studies 
combine to provide a body of experimental evidence which link alterations to the 
tRNA repertoire to tumour progression in vivo, and further investigation into these 
processes will likely contribute to effective strategies to oppose cancer progression 
and metastasis in humans.   
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MATERIALS AND METHODS 
Cell culture 
WM266.4, WM852 and iMEF lines were cultured in Dulbecco’s Modified Eagle 
Medium (Life Technologies) supplemented with L-glutamine (200µM) and 10% foetal 
calf serum. Stable pools were created by transfection with a pLHCX vector which 
had had its pCMV promoter removed via restriction digest to allow correct 
expression of the inserted tRNAs from their internal promoters. Pools were selected 
for and subsequently in maintained in 250µg/ml Hygromycin. 
Melanocyte culture was conducted at P2. Pups were placed in ice cold 70% ethanol 
for no longer than 30 seconds. Skin was dissected off, cut into pieces and incubated 
with 1.5 ml each of collagenase type 1 and 2 at 37ºC, 5% CO2 for 40 mins in 6 well 
plates. Contents were transferred in to 15 ml wash buffer (1xHBSS, 1mM CaCl2, 
0.005% DNase1) and centrifuged at 1100 RPM for 5mins. Pellets were resuspended 
in dissociation buffer and incubated at 37ºC, 5% CO2 for 10 mins. Tissue was then 
passed through an 18G needle and transferred to 10 ml wash buffer and allowed to 
settle. Grease and fur was removed from top of buffer and samples spun at 1100 
rpm for 5 mins. Cells were washed in PBS and then plated in 6 well plates at 1 x 106 
per well in Hams F-12 media with 10% FCS and 200nM TPA. To selectively reduce 
fibroblast growth, 50 µg/ml G418 was added to the media after 2 days. 
For cell proliferation assays 10,000 cells/well were plated in 6 well tissue culture 
plates (Falcon, Corning Inc) and total cell number counted 24, 48, 72 and 96 hours 
post plating (Casy Cell Counter, Innovatis AG). In each assay, the media was 
refreshed every 48 hours, and each well counted three times, with the average value 
being recorded, experiment repeated three times.  
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Generation of the 2+tRNAiMet mice 
Two copies of murine tRNAiMet gene (trna78), including ~140bp flanking sequences 
were targeted into the HPRT locus of HM1 embryonic stems cells which were used 
to generate chimeric mice from which tRNA iMet Trangenic offspring were derived by 
crossing to C57Bl/6 mice.  The generation of these mice and the breeding strategy 
for this is described in (Clarke et al, 2016).   
 
Generation of tRNA expression vectors 
To produce vectors without an exogenous pol II promoter, fragments containing 
tRNAiMet, tRNAeMet, and tRNAThr were cloned into the multiple cloning site of pLPCX 
using EcoR1. In parallel, pLHCX was digested with HpaI and SnaBI to remove the 
pCMV promoter. The tRNA containing pLHPX vectors were then digested with BglII 
and ClaI to release the tRNA containing fragments and these were subsequently 
cloned into the promoterless pLHCX vector that had been digested with BglII and 
ClaI. 
 
Metabolic Labelling 
Cells were grown to 80- 90% confluence, washed 2 x in PBS and then 5ml DMEM (-
methionine and cysteine) containing 10% dialysed foetal calf serum and L-glutamine 
to deplete cells of methionine and cysteine. Cells were incubated for 30 min 37º, 5% 
CO2. The medium was aspirated and replaced with 2ml of pulse labelling solution (as 
medium above but with 0.22mCi EasyTag added) and cells incubated for 20 min 37º, 
5% CO2, washed with cold PBS and then scrapped into ice-cold PBS into 15ml 
falcons. 20µl of cell suspension was added to BSA/NaN3 (1mg/ml BSA in 0.02% 
sodium azide) and TCA precipitated in 1ml ice cold TCA, vortexed and incubated 30 
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min on ice. 20 µl of cell suspension was also kept for total count and the rest of the 
cells spun and lysed for measurement of total protein concentration. The precipitated 
material was filtered on to Whatman GF/C 2.5 cm filter paper, and the filters washes 
2 x 5ml ice cold 10% TCA, 2 x 5ml ethanol, and then air dried for 30 mins. The cell 
suspension kept back for total count was spotted on to filter paper and dried. 
Scintillation fluid was added and filters counted using a Microbeta Trilux scintillation 
counter (Perkin Elmer). 
 
Cell motility assays 
For confluent monolayer scratch assays, cells were grown to confluence in 6 well 
dishes, scratched with a sterile pipette tip, washed and 4ml of fresh media added. 
For subconfluent migration, cells were plated at approximately 2 x 105 in 6 well 
plates. siRNA transfection was conducted 72h prior to timelapse. Migration was 
captured by timelapse capturing images every 15 mins (10 mins for subconfluent 
iMEFs). Migration velocity was calculated using single cell tracking via ImageJ 
analysis. 
For inverted invasion assays, Matrigel (BD biosciences) was polymerised in 
Transwell permeable inserts (Corning) at 37ºC, 5% CO2 for 1h. Inserts were inverted 
and 2-5 x 104 cells seeded onto the filter surface. Cells were allowed to adhere for 2-
3 h at 37ºC, 5% CO2. Inserts were washed 3 x in serum free medium. After final 
wash inserts were placed in serum free medium and medium plus 10% foetal calf 
serum added above the Matrigel to act as a chemo-attractant.  Invasion assays were 
prepared 24 h after siRNA or plasmid transfection. After 72h invading cells were 
stained with Calcein-AM and visualised via confocal microscopy through optical 
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sections obtained in the z-plane at 15µm intervals Quantification was conducted 
using ImageJ Area calculator plugin.  
 
siRNA and Vector Transfection 
5nM (20nM for integrin α5) siRNA were transfected into 5 x105 cells using Hiperfect 
(Qiagen) and pol III oligos (si 1 CAAGUAUGGUGACAUCGU, Ambion pre-designed 
s21945:, si 2 UCUAACCGUGGUUUCUCAAUUGGGA, Invitrogen custom Stealth 
RNA), TFIIIC (CAGUGAACGGAGAACGAU, Ambion pre-designed s6327), human 
integrin α5 (Thermo Scientific ON-TARGET SMARTpool L-008003-00; #1 which is 
UCACUACGCUCUCAACUUC; #2 which is ACACGUUGCUGACUCCAUU), mouse 
integrin α5 (Thermo Scientific ON-TARGET SMARTpool L-060502-01-0005; #1 
which is ON-TARGET J-060502-09; #2 which is J-060502-11) or non-targeting 
oligonucleotides in 6 well plates. 2.5µg of plasmid were transfected in 6 well plates 
using polyfect (Qiagen) for melanoma cell lines and human fibroblasts or TransIT 
(Mirus) for iMEF lines. 
 
Embryo analysis and β-galactosidase staining 
Embryos were dissected at E13.5 after detection of a vaginal plug at E0.5 and fixed 
in 0.25% gluteraldehyde at 4ºC for 45 mins on a rolling platform. Embryos were 
washed in PBS at 4ºC on rolling platform for 15 mins followed by 3 x 30 min washes 
in 2mM MgCl2, 0.01% Na-deoxycholate, 0.02% NP-40 in PBS at room temperature. 
β-galactosidase substrate (1M MgCl2, 0.02% NP-40, 0.01% Na-deoxycholate, 0.04% 
X-Gal, 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6) was added and embryos incubated in 
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darkness on rota overnight followed by incubation in 4% paraformaldehyde for 2h at 
4ºC. 
 
qPCR analysis 
cDNA was prepared with Qiagen Quantitech Reverse Transcription kit from 5, 10 or 
20 ng of RNA extracted from cells using Trizol. qPCR was conducted using BioRad 
CFX platform, at annealing temperature of 60ºC. Primer pairs: tRNAiMet F 
AGAGTGGCGCAGCGGAAG, R GAGGATGGTTTCGATCCATC; tRNAeMet F 
CCTCTTAGCGCAGCGGGC, R GCCCTCTCTGAGGCTCGAACTC; tRNAIle F 
GGCGGCCGGTTAGCTCAG, R CCCGTACGGGGATCGAAC; tRNATyr F 
CCTTCGATAGCTCAGCTGGTA, R AGCGACCTAAGGATGTCCGC; tRNALeu F 
ATGGCCGAGTGGTCTAAGG, R ACCAGAAGACCCGAACACAG; 5S F 
CAGCACCCGGTATTCCCAGG, R GGCATACCACCCTGAACGC . 
Genomic DNA was extracted from 12.5mg mouse lung tissue using Qiagen 
DNaeasy kit. The proportion of human genomic DNA was anaysed by performing 
qPCR on 7ng of lung DNA using human specific primers (F 5’ –
CATCCCTGGACTGATTGTCA, R 5’ – GGTTGGCCAGGTACATGTTT) or mouse 
specific primers (F 5’- CAGCGCTAGAGTGAGCGGATTA, R 5’ 
GAATTGATCAGTCTGCAGACAGCC).  
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Xenograft Experiments 
1 x 106 were either subcutaneously or intravenously injected via the tail vein into CD1 
nude mice. Subcutaneous tumour growth was measured by callipers three times a 
week until they reached a size endpoint of 15mm. Intravenously injected mice were 
taken at a designated timed endpoint. 
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Figures 
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 Fig. 1 Elevated levels of tRNAiMet promote α5β1-dependent cell migration 
(A) Immortalised mouse embryonic fibroblasts (iMEFs) were stably transfected with 
a vector encoding tRNAiMet or an empty vector control (vect.) (2 independent pools of 
each).  The migration speed of cells plated subconfluently, or of those moving into 
scratch-wounds was determined using time-lapse microscopy followed by cell 
tracking.  Representative cell trajectories are displayed in the left panels.  Data are 
represented as box and whiskers plots (whiskers: 10 - 90 percentile), n=3 
independent experiments, n=3 independent experiments, ****p<0.0001, ***p<0.001, 
Mann-Whitney test.  Bar, 100 μm. 
(B) iMEFs expressing tRNAiMet or an empty vector control (vect.) were transfected 
with siRNAs targeting α5 integrin (siRNA-α5; either a SMARTPool or two individual 
siRNA oligonucleotides as indicated), a non-targeting control (siRNA-nt) (right panel) 
or were left untransfected (left and centre panels).  Cell were plated onto plastic 
surfaces in the presence of blocking antibodies against α5 integrin (mAb16; left 
panel), the RGD-containing integrin-binding site in fibronectin (16G3; centre panel) 
or the appropriate isotype-matched control antibody (IgG).  Cell migration speed was 
then determined as for (A).  Data are represented as box and whiskers plots 
(whiskers: 10 - 90 percentile), n=3 independent experiments, n=3 independent 
experiments, ****p<0.0001; ns, not significant Mann-Whitney test. 
(C) Conditioned medium was collected from iMEFs stably transfected with a vector 
encoding tRNAiMet or an empty vector control.  Conditioned medium was then 
incubated with iMEFs and the migration speed of these cell determined as for (A).  
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Data are represented as box and whiskers plots (whiskers: 10 - 90 percentile), n=3 
independent experiments; ns, not significant Mann-Whitney test. 
(D)  iMEFs expressing tRNAiMet were transfected with siRNAs targeting collagen II 
(siRNA-Col2) or a non-targeting control (siRNA-nt), or iMEFs that had the collagen II 
gene disrupted using CRISPR (CRISPR-Col2) and their appropriate CRISPR control 
(CRISPR-Con) (see (Clarke et al, 2016)) and their migration speed was determined 
as for (A). Data are represented as box and whiskers plots (whiskers: 10 - 90 
percentile), n=3 independent experiments; ns, not significant, Mann-Whitney test. 
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Fig. 2  tRNAiMet-driven cell migration is dependent on translation initiation 
ternary complex formation 
iMEFs stably expressing tRNAiMet or vector control (vect.) were treated with 
salubrinal (75 μM) or vehicle control (DMSO) for 2hr (A).  Alternatively these cells 
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were transfected with a vector encoding the phosphatase, GADD34 or mock control 
(B).  iMEF migration speed was then determined as for Fig. 1(A).  The trackplots 
indicate representative migration trajectories of these cells over a 17 hr period.  The 
Western blots indicate the influence of salubrinal and GADD34 overexpression on 
levels of phosphorylated eIF2α.  Data are represented as box and whiskers plots 
(whiskers: 10 - 90 percentile); n=3 independent experiments; ****p<0.0001; ns, not 
significant, Mann-Whitney test.  Bar, 100 μm. 
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Fig. 3  Elevated expression of tRNAiMet drives melanoblast migration in the 
developing embryo 
(A)  Wild type (wt) and 2+tRNAiMet mice were crossed with a line expressing β-
galactosidase under a melanoblast-specific promoter (DCT-LacZ). Embryos were 
removed at day 13.5 of embryonic development (E13.5) and stained for β-
galactosidase expression to visualise melanoblasts (A), and the total number (B; left 
panel) and proportion of β-galactosidase-positive cells within regions 4 – 6 (right 
panel) of the forelimbs was scored (B, centre and right panels).  Data are 
represented as box and whiskers plots (whiskers: 10 - 90 percentile); *p<0.05; ns, 
not significant; Mann-Whitney test;. 
(C)  Wild type and 2+tRNAiMet mice were crossed with animals that were null for 
p16INK4A and that expressed a mutant allele of NRas under the melanoblast-
specific tyrosinase promoter (Tyr-NrasQ61K; INK4a−/−).  Melanocyte cell lines derived 
from the early pup skin of these Tyr::NrasQ61K/°; INK4a−/−; wild-type (wt) and 
Tyr::NrasQ61K/°; INK4a−/−; 2+tRNAiMet mice were plated onto plastic surfaces and their 
migration determined using time-lapse microscopy as for Fig. 1A.  Data are 
represented as box and whiskers plots (whiskers: 10 - 90 percentile) and as mean ± 
SEM as indicated; *p<0.05, ***p<0.001, Mann-Whitney test. 
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 Fig. 4  Elevated levels of tRNAiMet promote migration and invasion of 
melanoma cells 
(A)  Untransfected WM852 melanoma cells (WM852) or those stably transfected with 
a vector encoding tRNAiMet (two independent pools), tRNAeMet, or an empty vector 
control (vect.) were plated onto plastic dishes and their migration speed determined 
as for Fig 1A.   
(B) Control (Vect.) and tRNAiMet–expressing WM852 cells (pool 2 from (A)) were 
transfected with siRNAs targeting α5 integrin (siRNA-α5; either a SMARTPool or two 
individual siRNA oligonucleotides as indicated) or a non-targeting control (siRNA-nt) 
(right panel), or were left untransfected (left and centre panels).  Migration of these 
cells was then determined as for Fig. 1A in the presence and absence of an α5β1 
integrin blocking antibody (mAb16), an antibody which blocks integrin-fibronectin 
association (16G3) or the appropriate isotype–matched control antibodies (IgG).   
(C)  WM266.4 melanoma cells were stably transfected with a vector encoding  
tRNAiMet (two independent pools), tRNAeMet, tRNAThr or empty vector (vect.) (two 
independent pools).  Cells were allowed to migrate into Matrigel plugs towards a 
gradient of EGF and serum for 72 hr, and then visualised by Calcein-AM followed by 
confocal microscopy. Optical sections were taken every 15μm and consecutive 
images are displayed as a series running from left to right (C; left panels). Cell 
invasion beyond 45μm was quantified (C; right panel).   
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Data in (A-C) are represented as box and whiskers plots (whiskers: 10 - 90 
percentile). ****p<0.0001, *** p<0.001; ns, not significant; Mann-Whitney test.  All 
data are from at least 3 independent experiments with multiple internal replicates.  
(D)  WM266.4 cells stably transfecting with a control vector (Vect.) or tRNAiMet (two 
independent pools of each) were plated onto plastic dishes and their rate of 
proliferation over a 96 hr period was determined by cell counting.  Values are mean 
± SEM, n=3.   
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Fig. 5  tRNAiMet drives melanoma metastasis, but not primary tumour growth 
(A)  WM266.4 cells stably expressing a vector encoding tRNAiMet (two independent 
pools) or an empty vector (vector) (two independent pools) and were injected 
subcutaneously into the flank of CD1 nude mice.  Subcutaneous tumour growth was 
measured by callipers three times a week and tumour volume was calculated from 
these.  Values are mean ± SEM. 
(B)  tRNAiMet and empty vector expressing WM266.4 cells were injected 
subcutaneously into CD1-nude mice.  The resulting tumours (5 from each condition) 
were lysed and their fibronectin and β1 integrin content determined by Western 
blotting.  HSP70 is used as a loading control. 
(C, D)  tRNAiMet and empty vector expressing WM266.4 cells (two independent pools 
of each as for (A)) were injected via the tail vein into CD1 nude mice.  The lungs of 
these animals were assessed for the presence of tumours by visual inspection (B), 
by determination of lung weight (n = 7 + 7 pool 1 and 7 + 9 pool 2, pLHCX and 
tRNAiMet respectively) (C), and by qPCR to quantify the proportion of human genomic 
DNA (from the WM266.4 cells) with respect to mouse genomic DNA (from the host 
animal).  n = 7 + 7 pool 1 and 7 + 11 pool 2, vector and tRNAiMet respectively. Values 
are expressed as box and whiskers plots (whiskers: 5 - 95 percentile).  The ratios of 
human to mouse DNA are expressed on a Log10 scale.  **p<0.01, p<0.05, van 
Elteren Test (stratified Mann-Whitney). N.B. The injection of cells from pool 1 and 
pool 2 were conducted in experiments that were independent from one another. 
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Fig. 6.  Pol III and its products are associated with invasion and metastasis 
Heat maps from Oncomine data sets showing pol III (POLR3), TFIIIC (GTF3C) and 
TFIIIB (Brf1, BDP1) subunit mRNA expression in primary tumours versus patient-
matched metastases in melanoma (Xu and Riker datasets; A & B) or prostate cancer 
(Grasso dataset; C). The heatmap scale bar is indicated at the top, and the average 
degree of upregulation of transcripts in metastasis and statistical significance values 
of these are tabulated on the right-hand side.  In Oncomine, all data are normalised 
as follows: negative values were not included and all data were log2-transformed, 
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median-centred per array, and the standard deviation was normalised to one per 
array. Depending on the type of microarray (one or two-colours) data are presented 
either as log2 median-centered intensities (Xu & Riker), or log2 median-centered 
ratios (Grasso). The scale bar is log2.   
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Supplementary information for Birch et al. - tRNAiMet and invasion 
 
Fig. S1.  Suppression of α5 integrin in iMEFs and WM852 cells using siRNA. 
tRNAiMet overexpressing iMEFs (A) or WM852 cells (B) were transfected with 
siRNAs targeting α5 integrin – either using a SMARTPool (SP) or individual siRNA 
oligonucleotides (#1 & #2).  48 hr following transfection levels of α5 integrin were 
determined using Western blotting.  β-actin was used as loading control.   
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 Fig. S2  Manipulation of tRNA levels in melanoma cells 
(A) WM852 cells were transfected with vectors encoding tRNAiMet, tRNAeMet, or an 
empty vector control (vector) and pools of these were selected for stable expression 
of these Pol III products.  Levels of tRNAiMet were determined using qPCR.  Values 
are mean.   
(B)  WM266.4 cells were transfected with vectors encoding tRNAiMet, tRNAeMet, 
tRNAThr or an empty vector control (vector) and pools of these were selected for 
stable expression of these Pol III products.  Levels of tRNAiMet (left panel), tRNAeMet 
(centre panel) and tRNAThr (right panel) were determined using qPCR.  Values in the 
left panel are mean ± SEM; *p<0.05, **p<0.01 Mann Whitney test.  Values in the 
centre and right panels are mean.   
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tRNAiMet overexpressing iMEFs (A) or WM852 cells (B) were transfected with 
siRNAs targeting α5 integrin – either using a SMARTPool (SP) or individual siRNA 
oligonucleotides (#1 & #2).  48 hr following transfection levels of α5 integrin were 
determined using Western blotting.  β-actin was used as loading control.   
 
Biology Open (2016): doi:10.1242/bio.019075: Supplementary information
B
io
lo
gy
 O
pe
n 
• 
S
up
pl
em
en
ta
ry
 in
fo
rm
at
io
n
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empty vector control (vector) and pools of these were selected for stable expression 
of these Pol III products.  Levels of tRNAiMet were determined using qPCR.  Values 
are mean.   
(B)  WM266.4 cells were transfected with vectors encoding tRNAiMet, tRNAeMet, 
tRNAThr or an empty vector control (vector) and pools of these were selected for 
stable expression of these Pol III products.  Levels of tRNAiMet (left panel), tRNAeMet 
(centre panel) and tRNAThr (right panel) were determined using qPCR.  Values in the 
left panel are mean ± SEM; *p<0.05, **p<0.01 Mann Whitney test.  Values in the 
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